Literature DB >> 28941330

Purity of islet preparations and 5-year metabolic outcome of allogenic islet transplantation.

K Benomar1,2,3, M Chetboun2,3,4, S Espiard1, A Jannin1, K Le Mapihan1, V Gmyr2,3, R Caiazzo2,3,4, F Torres2,3,4, V Raverdy2,3,4, C Bonner2,3, M D'Herbomez5, P Pigny5, C Noel6, J Kerr-Conte2,3, F Pattou2,3,4, M C Vantyghem1,2,3.   

Abstract

In allogenic islet transplantation (IT), high purity of islet preparations and low contamination by nonislet cells are generally favored. The aim of the present study was to analyze the relation between the purity of transplanted preparations and graft function during 5 years post-IT. Twenty-four patients with type 1 diabetes, followed for 5 years after IT, were enrolled. Metabolic parameters and daily insulin requirements were compared between patients who received islet preparations with a mean purity <50% (LOW purity) or ≥50% (HIGH purity). We also analyzed blood levels of carbohydrate antigen 19-9 (CA 19-9)-a biomarker of pancreatic ductal cells-and glucagon, before and after IT. At 5 years, mean hemoglobin A1c (HbA1c levels) (P = .01) and daily insulin requirements (P = .03) were lower in the LOW purity group. Insulin independence was more frequent in the LOW purity group (P < .05). CA19-9 and glucagon levels increased post-IT (P < .0001) and were inversely correlated with the degree of purity. Overall, our results suggest that nonislet cells have a beneficial effect on long-term islet graft function, possibly through ductal-to-endocrine cell differentiation. ClinicalTrial.gov NCT00446264 and NCT01123187.
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research/practice; graft survival; islet isolation; islet transplantation; stem cells

Mesh:

Substances:

Year:  2017        PMID: 28941330     DOI: 10.1111/ajt.14514

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  5 in total

Review 1.  Advances in β-cell replacement therapy for the treatment of type 1 diabetes.

Authors:  Marie-Christine Vantyghem; Eelco J P de Koning; François Pattou; Michael R Rickels
Journal:  Lancet       Date:  2019-09-15       Impact factor: 79.321

Review 2.  Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions.

Authors:  Michael R Rickels; R Paul Robertson
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

3.  The challenge of HLA donor specific antibodies in the management of pancreatic islet transplantation: an illustrative case-series.

Authors:  Mehdi Maanaoui; Mikael Chetboun; Isabelle Top; Vincent Elsermans; Julie Kerr-Conte; Kristell Le Mapihan; Frederique Defrance; Valéry Gmyr; Thomas Hubert; Myriam Labalette; Marc Hazzan; Marie-Christine Vantyghem; François Pattou
Journal:  Sci Rep       Date:  2022-07-21       Impact factor: 4.996

4.  Selective Osmotic Shock for Islet Isolation in the Cadaveric Canine Pancreas.

Authors:  Elizabeth M Thompson; Jennifer L Sollinger; Emmanuel C Opara; Christopher A Adin
Journal:  Cell Transplant       Date:  2018-06-05       Impact factor: 4.064

5.  "Old School" Islet Purification Based on the Unit Gravity Sedimentation as a Rescue Technique for Intraportal Islet Transplantation-A Case Report.

Authors:  Justyna E Gołębiewska; Karolina Gołąb; Tomasz Gorycki; Maciej Śledziński; Jacek Gulczyński; Iwona Żygowska; Bogumił Wolnik; Michał Hoffmann; Piotr Witkowski; Camillo Ricordi; Edyta Szurowska; Zbigniew Śledziński; Alicja Dębska-Ślizień
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.